© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
An overview of data supporting exciting developments in hepatocellular carcinoma using systemic therapy in various treatment settings.
August 6th 2021
A brief overview of criteria and tools used to assess, and risk stratify patients with early stage hepatocellular carcinoma.
The rationale for diagnostic imaging to evaluate and diagnose early stage hepatocellular carcinoma.
August 13th 2021
A debate regarding the current role of biopsy to confirm a diagnosis of early-stage hepatocellular carcinoma.
Edward Kim, MD, of Mount Sinai Health System describes where advances in locoregional therapy for early-stage hepatocellular carcinoma fit into the therapeutic landscape.
August 20th 2021
University of Arizona’s Rachna Shroff, MD, describes the role of systemic therapy with locoregional treatment for early stage hepatocellular carcinoma and highlights treatment strategies of interest that remain under investigation.
Reactions to treatment gaps in the neoadjuvant space for hepatocellular carcinoma and implications for incorporating data supporting newer, novel systemic therapies for appropriate patients.
August 27th 2021
Reactions to recent clinical abstracts that support the use of hepatic arterial infusions for chemotherapy delivery in hepatocellular carcinoma.
Perspectives regarding treatment advances using adjuvant approaches that include immunotherapy to treat early-stage hepatocellular carcinoma.
September 3rd 2021
Best practices using available scoring systems to evaluate and treat patients with advanced hepatocellular carcinoma.
Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.
September 10th 2021
Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.
An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.
September 17th 2021
Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.
A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.